Max D. Adams, vice president (retired), Imaging Group, Mallinckrodt Tyco, St. Louis, Mo. Bachelor's degree, West Virginia University, 1965. Master's and doctoral degrees, Purdue University, 1968 and 1971, respectively. Upon receiving his doctorate, Adams accepted an academic position at the Medical College of Virginia, where he served for six years. In 1977, he began an industry career with Mallinckrodt Inc. as a senior research pharmacologist. At Mallinckrodt, Adams served in numerous capacities, including director of radiology and cardiology for research and development in the Science & Technology Division of Mallinckrodt Medical. From 1997 until his retirement from Mallinckrodt in 2001, Adams was vice president of imaging research and development. Since his retirement, he remains active as a scientific consultant serving startup pharmaceutical and medical product companies in the St. Louis area. During his career, Adams was an active researcher in the areas of pharmacologic and toxicologic evaluation of diagnostic contrast media, drug development and product registration, cardiovascular pharmacology, and hypertension and antihypertensive drugs. He has published numerous scientific articles and has been invited to present talks on these topics to professional organizations nationwide.
Jean M. Battaglia, senior director, Product Compliance Services, Worldwide Medicines Group, Bristol-Meyers Squibb Co., New Brunswick, N.J. Bachelor's degree, Saint Norbert College, 1970. Doctorate, industrial and physical pharmacy, Purdue University, 1973. After receiving her doctorate from Purdue, Battaglia joined the Squibb Institute for Medical Research as a research investigator, working on the preformulation and phase I clinical supply manufacture of anti-inflammatory and topical steroid compounds. She was promoted to supervisor in 1976, and in 1977 she was named section head of the quality organization of E.R. Squibb and Sons. After serving in positions of increasing responsibilities, Battaglia remains at Bristol-Myers Squibb Co. as senior director of consolidated site services, responsible for developing and directing global stability, statistics, quality compliant and testing standard programs for the company's pharmaceutical network. Throughout her career, Battaglia has been involved in multidisciplined programs and task forces for productivity, activity value analysis, strategic planning and recruiting. She has been recognized for developing practical operational procedures used by quality management at domestic and international sites that assure compliance with company standards and government regulations. She is a member of the Bristol-Myers Squibb Quality Leadership Council and remains active in college recruitment for leadership and diversity for Technical Operations.
Curtis D. Black, Merck Professor of Clinical Pharmacy and assistant dean for academic programs, College of Pharmacy, University of Toledo, Toledo, Ohio. Bachelor's degree, University of Toledo, 1974. Master's and doctoral degrees, clinical pharmacy, Purdue University, 1976 and 1978, respectively. Black began his academic career at Purdue as assistant professor of clinical pharmacy and established a practice at St. Elizabeth's Hospital in Lafayette. He also collaborated with Professor Dorothy Morré from the School of Foods and Nutrition to study the influence of specific nutrient regiments on tumor growth, work that has since branched into investigative studies with cancer in experimental models and human systems. At Purdue, Black served as associate head of pharmacy practice from 1986 until his departure in 1990. He then joined the faculty at the University of Toledo as Merck Professor of Clinical Pharmacy and currently serves as assistant dean for academic affairs and chair of the Department of Pharmacy Practice. At Toledo, Black's collaborative efforts in teaching, research, and practice have contributed to the development of experiential training sites for community pharmacy residency programs, an elective course in clinical laboratory medicine, and courses in professional practice development and pharmaceutics. He is credited with more than 50 publications, a book chapter, and four monographs. At Toledo, Black has been awarded two outstanding teacher awards from the College of Pharmacy, and an outstanding university professor award. He has been selected by the American Council on Pharmaceutical Education to serve as an accreditation team member for professional programs in pharmacy.
Frank Brown Jr., director, pharmaceutical sciences program, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Ind. Bachelor's degree, Southern University and A&M College, 1964. Doctoral degree, chemistry, Purdue University, 1969. A native of Detroit, Brown grew up and received his early education in Detroit and in Clinton, La. From 1968 until his retirement in 2000, Brown served as a chemist for API manufacturing and chemical process development at Lilly Research Laboratories, a division of Eli Lilly and Co. During his years at Lilly, Brown served in numerous capacities, and, in 1994, was named chief scientist at Lilly's Clinton Laboratories near Terre Haute, Ind. In that position, he also served as scientific and quality assurance consultant at Lilly manufacturing sites in Puerto Rico, the United Kingdom, Germany, Spain and Italy. Brown has conducted research and development on innovative products for human medicine, animal health and plant science products. He also has served as consultant to the Food and Drug Administration, the Environmental Protection Agency, and has testified as an expert witness in federal and European courts during patent and Department of Commerce litigation. After retiring from Lilly in 2000, Brown joined the Purdue School of Pharmacy and Pharmacal Sciences as an adjunct professor. He was later named manager of the Pharmacy Industrial Internship Program. In 2001, he became director of the Pharmaceutical Sciences Program while retaining his responsibilities with the Pharmacy Industrial Internship Program and serving as a visiting professor of chemistry at Purdue. As a civic leader, Brown has served as an officer and director of Lafayette Home Hospital and a representative on the hospital's board of directors.
Arthur J. Fiocco Jr., vice president of manufacturing, Baxter BioScience Group, Baxter Healthcare Corp., Los Angeles, Calif. Bachelor's degree, Temple University, 1982. After receiving a bachelor's degree in pharmacy from Temple University, Fiocco pursued a career in technical operations in the pharmaceutical industry. In 1982, he joined Schering-Plough in New Jersey as a process validation engineer, where he was promoted to plant manager in 1988. In 1990, he was promoted to general manager in Las Piedras, Puerto Rico, managing a 500-employee manufacturing operation. In 1994, Fiocco returned to New Jersey as the senior director, New Jersey Operations, responsible for three manufacturing plants supporting sales of $4 billion. In this position, he hosted off-site training programs for the Food and Drug Administration's inspections. In 2000, Fiocco joined Baxter Healthcare Corporation's BioScience Group in Los Angeles as vice president of manufacturing. A strong supporter of Purdue and the School of Pharmacy, Fiocco has been recognized as a champion of the Pharmacy Minority Program and has received several recognition awards in leadership, management development and management excellence. He is a member of the Purdue pharmacy dean's advisory council and has been a guest lecturer at Purdue and key figure in the student summer internship and industry career mentoring programs. Fiocco is a registered pharmacist in New Jersey and a member of the American Pharmaceutical Association and the Parenteral Drug Association.
Mark A. Foglesong, executive director of animal health and cephalosporin networks, Eli Lilly and Co., Indianapolis. Bachelor's, master's and doctoral degrees in microbiology, University of Iowa, 1971, 1972 and 1974, respectively. Following his academic training, Foglesong joined Eli Lilly and Co. as a senior microbiologist. At Lilly, he was promoted to research scientist in 1980, manager in 1984, director of fermentation process research and development in 1989, and director of biochemical manufacturing operations in 1990. In 1993, he was named executive director of manufacturing facilities and strategic planning, and, in 1994, was promoted to general manager of manufacturing for Europe, Middle East and Africa. He moved to London and assumed responsibility for Lilly's manufacturing plants in the UK, Spain, France, Germany, Italy and numerous manufacturing operations in Eastern Europe and the Middle East. In 1998, Foglesong returned to Indianapolis and was later named executive director of Lilly's newly created supply chain operations organization. Over the last five years Foglesong has been a leader in Lilly's emergency response and crisis management organization, serving as assistant and corporate chief emergency response officer. In February 2002, after 27 years of service, Foglesong retired from Eli Lilly as executive director of animal health and antibiotic manufacturing operations. Foglesong served as chairman of the Pharmaceutical Manufacturers Association's Biotechnology Advisory Committee from 1990 until 1992. He also has served as a consultant to the U.S. Department of Defense, Department of State and Department of Commerce. For the past two years he has served as executive liaison between Lilly and Purdue's School of Pharmacy and Pharmacal Sciences. Foglesong is a member of the Purdue School of Pharmacy and Pharmacal Sciences Industrial Council.
James C. Mannion, president and chief operating officer, EpiGenesis Pharmaceuticals, Cranbury, N.J. Bachelor's degree, Ohio Northern University, 1976. Master's degree in pharmacy administration, 1977; doctoral degree in clinical pharmacy, 1982, Purdue University. Mannion's 20-year career in the pharmaceutical industry began in clinical drug research in respiratory medicines at Burroughs Wellcome Co., Research Triangle Park, N.C. After moving to Beecham Laboratories in Bristol, Tenn., he became group director of U.S. Regulatory Affairs for SmithKline Beecham Pharmaceuticals in Philadelphia. Mannion's experience includes respiratory, antibacterial, antiviral, antidepressant, cardiovascular, cancer, Alzheimer's disease, thrombolytic, metabolic and hormonal medicines. He has contributed to the development and introduction of some of the world's top selling pharmaceutical products. In 2000 Mannion accepted his current position as president and chief operating officer of EpiGenesis Pharmaceuticals, where he is responsible for daily operations and leadership in the development of business, drug discovery research, clinical development and regulatory strategies. Under his leadership, the company has expanded from seven to 40 staff members. He also serves as a member of the EpiGenesis' board of directors, and is a frequent guest speaker worldwide on topics ranging from innovative business models, strategic drug development and genomics-based medicines.
Charles Wayne McKeehan, head (retired), product development, Eli Lilly and Co., Indianapolis. A native of Greencastle, Ind., McKeehan received three pharmacy degrees from Purdue, including a bachelor's degree in pharmacy, 1951, and master's and doctoral degrees in pharmaceutical chemistry, 1953 and 1957, respectively. While in graduate school, McKeehan served in the U.S. Army as a scientist at the Army Medical Research Laboratory at Fort Knox, Ky., where he had the opportunity to contribute and serve as principal scientist in a number of reports and publications on the reflectance properties of animal and human skin. He continued this work in reflectometry while completing his doctoral degree in pharmaceutical chemistry at Purdue. Following graduation, McKeehan began an industrial career as a product development scientist at Eli Lilly and Co. At Lilly, he was responsible for pharmaceutical research and product development, then branched out into positions in marketing and chemical manufacturing. During his tenure at Lilly, McKeehan directed the development efforts of scientists in materials characterization of new drug substances and in developing new dosage forms for marketing. He was involved with the development of a number of significant products including Keflex, Ceclor, Prozac, Humatope and Humulin. Following his retirement from Lilly in 1991, McKeehan joined Executive Service Corps as a consultant and member of the board of directors. ESC is a group of retired executives and professionals who donate their time to assist government, non-profit agencies and small businesses in improving their operations.
Randall L. (Pete) Vanderveen, dean and professor, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pa. Bachelor's and master's degrees in clinical pharmacy, Purdue University, 1974 and 1976, respectively. While a graduate student at Purdue, Vanderveen was awarded the Merck Award for Excellence in Medicinal Chemistry. He completed a residency in hospital pharmacy at Bronson Methodist Medical Center in Kalamazoo, Mich., then earned a doctorate in university administration from Michigan State University in East Lansing. In 1999 he successfully completed the Board of Pharmaceutical Sciences certification process and became board certified as a psychiatric pharmacist. Vanderveen joined the faculty of Ferris State University in Kalamazoo as an off-campus instructor of clinical pharmacy in 1976, and was promoted to assistant professor of clinical pharmacy and director and department chairman for clinical pharmacy in 1978. He received tenure as associate professor in 1980. In 1988 Vanderveen moved to Oregon and became assistant dean for pharmacy practice at Oregon State University, successfully implementing Oregon State University's first Pharm.D. program. In 1998, he moved to Pittsburgh and was named dean of the School of Pharmacy, dean of the Graduate School, and professor of Pharmacy Practice at Duquesne University. Vanderveen has served as president of Michigan Society of Health-Systems Pharmacists and on the board of directors of the American Association of Colleges of Pharmacy. His practice activities include hospital pharmacy, community pharmacy, long-term care pharmacy, managed care pharmacy and clinical practice in psychiatry. His research interests have included natural products, practice and management, and educational strategies. He also has taught in the areas of pharmacokinetics, literature evaluation, communications, management and clinical therapeutics. Vanderveen's brother, Timothy, received a Distinguished Alumni Award from Purdue's School of Pharmacy and Pharmacal Sciences in 1989.